Ms4a6c, whose full name remains to be comprehensively defined, seems to be associated with myeloid cell-related functions. From the references, myeloid cells play critical roles in the central nervous system (CNS) immune defense, maintaining tissue homeostasis and responding to injury or disease [1].

In experimental autoimmune encephalomyelitis (EAE) mice, Ms4a6c shows differential expression. During the high clinical score (HCS) of EAE, its mRNA expression is increased. Herceptin treatment can reduce the levels of Ms4a6c mRNA, except in certain regimens where Cd74 and Clec7a also show increased levels at HCS [2].

In the context of CNS, long-term and brain-wide colonization of peripheral bone marrow-derived myeloid cells (monocytes) is achieved. A monocyte signature is identified, and Ms4a6c is among the genes with up-regulation in this signature. This long-term engraftment of monocytes in the CNS also induces brain region-dependent alterations in transcription profiles, astrocytes, neuronal structures, and cognition [1].

In conclusion, Ms4a6c appears to be involved in myeloid cell-related processes in the CNS, especially in the context of diseases like EAE. Its differential expression in EAE mice and its presence in the monocyte signature during CNS myeloid cell colonization highlight its potential importance in understanding CNS-related immune responses and disease mechanisms.